Indeed, a potentiating effect was shown between NAMPT inhibitors and the PARP inhibitors olaparib or niraparib in triple-negative breast cancer and Ewing sarcoma [151,152,153]. This evidence concerns the gene NAMPT and Ewing sarcoma.